Saying this one word can get you in big trouble. The FDA doesn't like it. And just a few years ago, 63% of cancer doctors said they would never use it with a patient.
| |
Dear Null, Saying this one word can get you in big trouble. The FDA doesn't like it. And just a few years ago, 63% of cancer doctors said they would never use it with a patient. But now... the top cancer doctors in the world are suddenly saying it. A lot. I personally just attended a conference with some of the most highly trained and paid oncologists in America – and this word was everywhere. And one of the smartest scientists I know just went "on record" with it in a big way. See what I mean, right here. Keep in mind: Mere whispers of this word have led to gains of 1,078%... 729%... even an extraordinary 19,996% in drug companies working on cancer. Now that this word is out there... the opportunity just got way, way bigger – worth an estimated $5 trillion over the next decade. That's why I'm certain this is the biggest financial opportunity we've ever shared with readers. More than that – it's a story that you must see if you've ever known anyone who's had to face cancer. Whether you like hearing this word or not doesn't matter to me in the least. I just saw this for myself. And I think it's vital you do too. I explain everything here. Regards, Steven Longenecker
Senior Editor, Stansberry Research |
|
|
All contents of this e-mail are copyright 2019 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.
You're receiving this email at [email protected]. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to [email protected].
To unsubscribe from this mailing, click here: Unsubscribe
|
|
|
